Remove Business Development Remove Dermatology Remove Hormones
article thumbnail

Amgen Reports Second Quarter 2021 Financial Results

The Pharma Data

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities.

Sales 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy.

Sales 98